Albireo reports q4 loss per share $0.57

Albireo reports fourth quarter and year-end 2019 financial results, and provides business update.q4 loss per share $0.57.q4 revenue $6.4 million versus $600,000.q4 revenue estimate $1.5 million -- refinitiv ibes data.q4 earnings per share estimate $-1.59 -- refinitiv ibes data.initiating pivotal trials in biliary atresia first half of 2020 and alagille syndrome by year end.albireo pharma - for full year 2020, co anticipates total expenses, including research and development and g&a expenses, to be around $100mln.albireo pharma - now anticipates that its current cash balance will be sufficient to meet its operating needs into second half 2021.
ALBO Ratings Summary
ALBO Quant Ranking